e-ISSN: Pending
Failed Experiment ReportOpen accessBiochemistry, Genetics and Molecular Biology· cited by 40

Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa

Michel Michaelides; Cagri G. Besirli; Yesa Yang; Thales A. C. de Guimarães; Sui Chien Wong; Rachel M. Huckfeldt; Jason Comander; José‐Alain Sahel · 2024 · American Journal of Ophthalmology

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract

PURPOSE: To assess the safety and efficacy of AAV5-hRKp.RPGR in participants with retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa (XLRP). DESIGN: Open-label, phase 1/2 dose escalation/expansion study (ClinicalTrials.gov Identifier: NCT03252847). METHODS: vg/ml) was administered to the poorer-seeing eye (n = 10). Dose confirmation (intermediate dose) was carried out in 3 pediatric participants. In the dose expansion phase, 36 participants were randomized 1:1:1 to immediate (low or intermediate dose) or deferred (control) treatment. The primary outcome was s

Abstract by Michel Michaelides; Cagri G. Besirli; Yesa Yang; Thales A. C. de Guimarães; Sui Chien Wong; Rachel M. Huckfeldt; Jason Comander; José‐Alain Sahel, American Journal of Ophthalmology (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.ajo.2024.05.034